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Abstract
Background: Breast, endometrial, and ovarian cancers share some hormonal and epidemiologic risk factors. While several
models predict absolute risk of breast cancer, there are few models for ovarian cancer in the general population, and none
for endometrial cancer.
Methods and Findings: Using data on white, non-Hispanic women aged 50+ y from two large population-based cohorts
(the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial [PLCO] and the National Institutes of Health–AARP Diet
and Health Study [NIH-AARP]), we estimated relative and attributable risks and combined them with age-specific US-
population incidence and competing mortality rates. All models included parity. The breast cancer model additionally
included estrogen and progestin menopausal hormone therapy (MHT) use, other MHT use, age at first live birth,
menopausal status, age at menopause, family history of breast or ovarian cancer, benign breast disease/biopsies, alcohol
consumption, and body mass index (BMI); the endometrial model included menopausal status, age at menopause, BMI,
smoking, oral contraceptive use, MHT use, and an interaction term between BMI and MHT use; the ovarian model included
oral contraceptive use, MHT use, and family history or breast or ovarian cancer. In independent validation data (Nurses’
Health Study cohort) the breast and ovarian cancer models were well calibrated; expected to observed cancer ratios were
1.00 (95% confidence interval [CI]: 0.96–1.04) for breast cancer and 1.08 (95% CI: 0.97–1.19) for ovarian cancer. The number
of endometrial cancers was significantly overestimated, expected/observed = 1.20 (95% CI: 1.11–1.29). The areas under the
receiver operating characteristic curves (AUCs; discriminatory power) were 0.58 (95% CI: 0.57–0.59), 0.59 (95% CI: 0.56–0.63),
and 0.68 (95% CI: 0.66–0.70) for the breast, ovarian, and endometrial models, respectively.
Conclusions: These models predict absolute risks for breast, endometrial, and ovarian cancers from easily obtainable risk
factors and may assist in clinical decision-making. Limitations are the modest discriminatory ability of the breast and ovarian
models and that these models may not generalize to women of other races.
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Introduction
Several statistical models predict a woman’s probability or
absolute risk of developing invasive breast cancer based on her age
and reproductive, medical, and lifestyle factors [1–5]. Many risk
factors associated with breast cancer are also associated with the
risk of other gynecologic cancers. For example, four of the seven
risk factors used in the publicly available Breast Cancer Risk
Assessment Tool (BCRAT; http://www.cancer.gov/bcrisktool)
[6] are also strongly associated with ovarian and endometrial
cancer risks, including current age, age at menarche, parity, and
first-degree family history of breast cancer. Therefore, a woman
with a high breast cancer risk due to combinations of these risk
factors likely also has above-average endometrial or ovarian
cancer risk. However, while some models have been proposed for
risk prediction for ovarian cancer [7], no model that predicts the
absolute risk of endometrial cancer is available, even though
endometrial cancer is the fourth most common cancer in women,
and 1 in 38 women will be diagnosed with endometrial cancer
during her lifetime [8]. With rates of obesity increasing and rates
of hysterectomy declining in many regions of the US, endometrial
cancer incidence may rise further, and thus it is important to
identify women at highest risk for this disease.
Absolute risk prediction models provide useful information for
health care providers and patients and aid in the design and
recruitment phase of studies of preventive interventions. Several
large chemoprevention studies of tamoxifen (Nolvadex; AstraZe-
neca) and raloxifene (Evista; Lilly) used BCRAT projected breast
cancer risk to determine eligibility and to estimate needed sample
sizes [9,10]. These models can also aid clinical management of
women at elevated risk of one or more of these outcomes. For
example, if a woman presents with endometrial bleeding, but is
found not to have endometrial cancer in a subsequent workup, an
estimate of her risk of developing endometrial cancer over the next
5 or 10 y may aid her and her physician in deciding further steps,
including having a hysterectomy or taking progestin. Knowing her
risk of endometrial cancer in addition to her risk of breast cancer
could also inform a woman’s decision about whether or not to
consider use of tamoxifen for breast cancer prevention [11], as
tamoxifen reduces breast cancer risk, but also increases the risk of
endometrial cancer [10]. Additionally, knowing her ovarian
cancer risk might influence her decision regarding prophylactic
bilateral oophorectomy to reduce her risk of breast cancer.
We developed absolute risk prediction models for breast,
endometrial, and ovarian cancer by combining data from two
large prospective cohorts at the National Cancer Institute (NCI)—
the Prostate, Lung, Colorectal, and Ovarian Cancer Screening
Trial (PLCO) and the National Institutes of Health–AARP Diet
and Health Study (NIH-AARP)—and from incidence and
competing mortality rates in the NCI’s Surveillance, Epidemiol-
ogy, and End Results Program (SEER). The SEER cancer
registries cover approximately 28% of the US population (http://
seer.cancer.gov/about/overview.html).
All models were validated using independent data from the
Nurses’ Health Study (NHS).
Methods
Data for Relative Risk Models
We used data on white, non-Hispanic women from two NCI
cohorts: the PLCO cohort and the NIH-AARP cohort.
PLCO. PLCO has been described in detail previously [12]. In
brief, PLCO enrolled 78,232 women, aged 55 to 74 y at baseline,
between November 1993 and June 2001 at ten screening centers.
Women were eligible if they had no history of lung, colorectal, or
ovarian cancer and were neither undergoing cancer treatment nor
participating in other screening or prevention trials. Women who
had undergone bilateral oophorectomy or were taking tamoxifen
were initially ineligible but were later included. Women random-
ized to the screening arm of the trial received a single-view chest
X-ray annually for 4 y to screen for lung cancer; a CA (cancer
antigen) 125 blood test annually for 6 y and a transvaginal
ultrasound yearly for 4 y, both to screen for ovarian cancer; and
flexible sigmoidoscopy at the beginning of the trial and either 3 y
or 5 y later to screen for colorectal cancer. Institutional review
boards at the NCI and screening centers approved the study.
At entry, participants completed a self-administered lifestyle
questionnaire. Cancers were ascertained via annual study updates
and death certificates, and verified via review of medical records.
NIH-AARP. NIH-AARP has been described previously [13].
It included 567,169 men and women who, in 1995–1996, were
50–71 y old and resided in one of eight states. Participants
returned a self-administered baseline questionnaire and a second
more detailed questionnaire, sent 6 mo after the baseline
questionnaire. The NCI Special Studies Institutional Review
Board approved the study.
Cancer cases were identified through linkage with state cancer
registries with a 90% completeness rate [14]. All cases had a
histologic diagnosis. Vital status was ascertained through annual
linkage to the Social Security Administration Death Master File
and the National Death Index Plus.
Analytic populations. In each study, we restricted the
analysis to non-Hispanic, white women who completed the
baseline questionnaire, had follow-up information, and had no
personal history of the cancer of interest at baseline. For the
ovarian and endometrial cancer models, we further excluded
women with bilateral oophorectomy or hysterectomy, respectively
(see Table 1 for further details on exclusions). After these
exclusions, the NIH-AARP and PLCO study populations included
191,604 and 64,440 women, respectively, for the breast cancer
analysis, 114,931 and 42,821 women, respectively, for the
endometrial cancer analysis, and 151,165 and 58,282 women,
respectively, for the ovarian cancer analysis.
Data for Model Validation
Independent data from the NHS cohort from July 1990 to June
2004 were used to validate our models. The NHS cohort included
121,701 women aged 30–55 y in 1976 [15]. All participants gave
informed consent at enrollment. With the same exclusions as for
the relative risk (RR) models, the validations were based on 57,906
women for the breast cancer model and 37,241 for the
endometrial cancer model. For the ovarian cancer absolute risk
model we additionally excluded women who reported removal of a
single ovary or ovarian surgery with unknown status of the ovaries
during follow-up, resulting in 56,638 women for validation. See
Table 2 for details on exclusions. Breast and ovarian cancer
incidence rates were similar to those in SEER, but endometrial
cancer incidence was substantially lower, with an overall incidence
at age 50–74 y of 42.16 per 100,000 person-years, compared to
78.1 per 100,000 person-years in SEER for the same age range
(see Tables 3 and 4 for further details).
Statistical Methods
Relative risk models. We estimated separate RR models for
breast, endometrial, and ovarian cancer using Cox proportional
hazards regression (SAS, version 9.1; SAS Institute), with age as
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the timescale. For each of the cancers, the primary outcome was
incident, invasive epithelial cancer. For each outcome we first
estimated RRs and 95% confidence intervals (CIs) separately for
each cohort. However, we used RRs from a Cox model for the
combined cohorts that included a study indicator as covariate
(NIH-AARP versus PLCO). Analyses of the combined data that
stratified the baseline hazard function in the Cox model on study
yielded results in agreement to the third decimal point with this
regression method. Proportionality of the hazard functions was
assessed by visual inspection of hazard plots and Schoenfeld
residuals.
For each RR model, women were considered at risk from the
age at study entry (randomization for PLCO and completion of
baseline questionnaire for NIH-AARP) until the age at the earliest
of the following: (1) diagnosis of cancer of interest, (2) death, or (3)
administrative censoring (for PLCO, most recent annual study
update through December 31, 2005; for NIH-AARP, December
31, 2003). In PLCO, women were also censored at date of
unconfirmed self-reported cancers and non-epithelial cancers (the
International Classification of Diseases for Oncology, Third Edition [16]
morphology codes 8000 to 8573). For the breast cancer RR
analysis, women were additionally censored at diagnosis of breast
carcinoma in situ, and for the ovarian cancer RR analysis, at
diagnosis of an ovarian tumor of low malignant potential in
PLCO.
We considered the following risk factors (coding in parentheses):
body mass index (BMI; ,25, 25 to ,30, 30 to ,35, 35 to ,40,
and 40+ kg/m2), age at menarche (see comment on coding below),
number of live-born children (parity; 0, 1, 2, 3–4, 5–9, 10+), age at
first birth (no children or at age ,16, 16–19, 20–24, 25–29, 30–
34, 35–39, 40+ y), duration of oral contraceptive (OC) use (never
or ,1, 1–4, 5–9, 10+ y), menopausal status and age at natural
menopause (still menstruating or age ,40, 40–44, 45–49, 50–54,
$55 y), status and duration of menopausal hormone therapy
(MHT) use (never, current use, former use; 0, ,5, 5–9, 10+ y),
status and duration of estrogen and progestin MHT use (never,
current use, former use; ,1, 2, 3, …, 9, 10+ y), duration of
unopposed estrogen MHT use (current use, former use, never;,1,
2, 3, …, 9, 10+ y), history of benign breast disease (yes/no) or
breast biopsy (0, 1, 2, 3+ biopsies), first-degree family history of
Table 1. Study populations and exclusions for model development: NIH-AARP and PLCO cohorts at baseline.
Cohort Subsets Breast Cancer Model Endometrial Cancer Model Ovarian Cancer Model
NIH-AARP PLCO NIH-AARP PLCO NIH-AARP PLCO
Total cohort 226,733 78,217 226,733 78,217 226,733 78,217
Proxy response/no baseline questionnaire 1,265 2,095 1,265 2,095 1,265 2,095
Non-white 23,920 8,720 23,920 8,720 23,920 8,720
Organ removed or unknown at baseline — — 86,587 24,189 49,956 8,608
No follow-up time after baseline 4 565 3 373 4 505
Prevalent cancer of interest 9,940 2,397 27 19 423 —
Analytic cohort for model building 191,604 64,440 114,931 42,821 151,165 58,289
Cases used for model building 5,870 2,288 1,185 471 597 284
Missing covariates 13,141 2,191 9,946 1,127 7,756 1,725
Final analytic cohort 178,463 62,249 104,985 41,694 143,409 56,564
Final number of cases used in the models 5,480 2,215 1,097 462 570 274
doi:10.1371/journal.pmed.1001492.t001
Table 2. Study population and exclusions for model validation: NHS cohort at baseline.
Cohort Subsets Breast Cancer Model Endometrial Cancer Model Ovarian Cancer Model
Total cohort 121,701 121,701 121,701
Age at entry ,50 y 24,366 24,366 24,366
Non-white 3,268 3,268 3,268
Prevalent cancer of interest 2,702 317 277
No follow-up time after baseline 3,710 4,180 4,030
Missing birth year 123 123 123
Organ removed/unknown at baseline — 32,712 16,512
Missing covariates 29,625 8,750 3,909
Age at exit $90 y 1 1 1
Organ removed/unknown during follow-up 10,743 12,577
Analytic cohort 57,906 37,241 56,638
Cases 2,934 532 377
doi:10.1371/journal.pmed.1001492.t002
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breast cancer (0, 1, 2+ first-degree relatives—mother, daughter, or
sister—with a breast cancer diagnosis), first-degree family history
of ovarian cancer (0, 1, 2+ first-degree relatives—mother,
daughter, or sister—with an ovarian cancer diagnosis), previous
gynecologic surgery (defined as hysterectomy and/or partial or
bilateral oophorectomy), history of endometriosis (yes/no), history
of uterine fibroids (yes/no), use of tobacco (never, former, current
smoker; cigarettes per day smoked) and alcohol consumption
(drinks/day), and serum CA 125 level at baseline (PLCO only).
For PLCO, we tested potential interactions with randomization
arm and, for ovarian cancer, method of detection (screen-detected
versus not screen-detected). In most instances, the PLCO and
NIH-AARP questionnaires allowed for identically coded variables.
To synchronize age at menarche (PLCO categories ,10, 10–11,
12–13, 14–15, 16+ y; NIH-AARP categories #12, 13–14, 15+ y),
we randomly allocated women in the overlapping PLCO
categories (e.g., 12–13 y) to the NIH-AARP categories (#12 y
or 13–14 y) using the age at menarche distribution from the
nationally representative NHANES study [17]. For OC use we
randomly assigned women in the #1 year category in PLCO to
the ,1 and 1+ year categories.
Alcohol consumption was not ascertained in the PLCO control
arm, and thus RRs for association with alcohol consumption were
estimated from the PLCO intervention arm and NIH-AARP. RRs
for duration of estrogen and progestin MHT use and duration of
unopposed estrogen MHT use were estimated from women in the
NIH-AARP cohort who had responded to the second question-
naire. Information for benign breast disease was missing on 20%
of the women in the dataset, and we thus created an indicator for
missing values. For all other variables, women with missing values
were excluded as the number missing was very small (,5% for all
variables; Table 5). We first assessed all risk factors listed above as
possible predictors for each cancer as main effects. Final models
included only variables that were significant in multivariable
models with p,0.01. We chose a stringent p-value as we did not
want to include variables with modest RRs that would not
improve prediction. Model building was repeated using stepwise
variable selection in Cox proportional hazards models and led to
the same variables being selected for each cancer. We also assessed
the significance at p,0.01 of all first-order interaction terms of
variables included in the final models. We fitted variables with
trends whenever appropriate. For all risk factors, the reference
category was the lowest risk category, to facilitate attributable risk
(AR) computations. To accommodate missing data, we calculated
AR for the breast cancer model in women with complete data.
Using time on study as the timescale, adjustment for calendar
period or additional censoring at age of diagnosis of any other
cancer (e.g., censoring the breast cancer models at diagnosis of
endometrial cancer or ovarian cancer) or adjustment for
gynecologic surgery did not change the results appreciably.
Absolute risk models. The absolute risk p(a,b) of cancer c
(c=breast, endometrial, or ovarian cancer) in the age interval (a,b]
is the probability of developing a specific cancer c during that
interval, given that one is alive and free of previous cancer c at the
beginning of the interval. The absolute risk is reduced by death
from causes other than cancer c and is defined by
p(a,b)~
ðb
a
l1(t,x) exp {
ðt
a
fl1(u,x)zl2(u)gdu
 
dt ð1Þ
In Equation 1, l1 and l2 are the cause-specific hazard rates for
cancer c and for competing causes, respectively.
We modeled l1(a,x) = l10(a) rr1(a,x) as the product of the age-
specific baseline hazard rate l1(a) and the RR model, rr1(a,x) =
exp(b’x), where x denotes covariates. We did not include covariates
in the hazard l2 for competing causes of death. The age-specific
baseline hazard rates l10(a) are computed by multiplying the age-
specific SEER incidence rates, l1*(a), by one minus the estimate of
Table 3. Age-specific incidence per 100,000 person-years in
non-Hispanic white women from the NHS cohort, ex luding
only women with prevalent cancer of interest and no positive
follow-up time.
Age Group Breast Cancer Endometrial Cancera Ovarian Cancer
50–54 y 293.2 40.7 25.1
55–59 y 312.5 42.8 34.1
60–64 y 352.0 40.2 36.3
65–69 y 347.1 45.0 40.8
All 325.5 49.7 34.0
aCancer of the corpus uteri or uterus, not otherwise specified.
doi:10.1371/journal.pmed.1001492.t003
Table 4. 5-y age-specific SEER incidence rates, 1992–2006, for breast, endometrial, and ovarian cancers for white, non-Hispanic
females in 13 SEER registries (Alaska excluded) that cover 14% of the US population.
Age Group Total Population Breast Cancer Endometrial Cancera
Endometrial Cancera
Corrected for
Hysterectomy Ovarian Cancer
Ovarian Cancer Corrected
for Bilateral Oophorectomy
50–54 y 11,228,901 272.42 50.50 76.24 25.93 32.20
55–59 y 9,134,183 338.62 77.50 127.55 33.50 41.61
60–64 y 7,379,976 410.08 97.44 174.72 43.47 59.28
65–69 y 6,692,181 465.29 106.50 193.67 49.06 70.61
70–74 y 6,386,868 499.40 109.02 199.96 56.15 73.12
75–79 y 5,797,382 518.48 106.05 196.35 60.25 81.59
80–84 y 4,460,480 491.45 96.76 172.35 62.68 85.04
85+ y 4,403,964 408.84 69.26 118.09 54.61 65.10
Source: SEER (http://seer.cancer.gov/).
aCancer of the corpus uteri or uterus, not otherwise specified.
doi:10.1371/journal.pmed.1001492.t004
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the AR, i.e., l10(a) = l1*(a)(12AR1(a)), as outlined in [2]. The AR
for cancer type c was obtained as one minus the number of women
in the dataset divided by the sum of the multivariate RR estimates
for cancer c over all women. We used a model with piecewise
constant hazards to approximate Equation 1, with 5-y age
intervals.
In SEER, endometrial and ovarian cancer incidence rates are
calculated based on all women in the population in a given age
group. These rates thus are lower than rates that are based on
women with an intact uterus or ovaries, respectively. We therefore
adjusted the age-specific SEER rates by dividing them by the
percentage of women who had not had a hysterectomy (estimated
from the Behavioral Risk Factor Surveillance System (BRFSS)
survey [18] for the same areas included in SEER) or oophorec-
tomy (estimated from NHANES [17]) (see Tables 4 and S1, S2,
S3). In Table S1 we also present rates for models that allow for the
possibility that a woman might have a hysterectomy or an
oophorectomy during the projection interval, by adding hysterec-
tomy and oophorectomy rates to the competing risks for the two
models, respectively.
Statistical analysis used for model validation. We
compared the expected and the observed numbers of cases overall
and in subgroups defined by risk factor combinations. The
expected number of cases was calculated by summing the
individual projected probabilities, given the baseline covariate
values for each woman from entry (July 1990) into the NHS cohort
to June 2004. The 95% CIs for the expected/observed (E/O)
ratios were calculated using the normal approximation to the
Poisson distribution:
E
O
e+1:96
ﬃﬃ
1
O
p
. An E/O ratio above one indi-
cates that the model overestimates cancer risk, and an E/O less
than one indicates that the model underestimates cancer risk. We
evaluated the discriminatory accuracy of the prediction models
using the area under the receiver operating characteristic curve
(AUC), with 95% bootstrap CIs.
Results
The characteristics of the women in the study and cancer
incidence rates are shown in Table 1.
Relative Risk Models
Breast cancer. Of the 240,712 women used to fit the final
breast cancer RR model, 7,695 were diagnosed with invasive
breast cancer. The following variables were included in the final
RR model: BMI (,25, 25 to ,30, 30 to ,35, 35+ kg/m2),
estrogen and progestin MHT use (never,,10, 10+ y), other MHT
use (no, yes), parity (0, 1+ children), age at first birth (,25, 25–29,
30+ y), premenopausal (no, yes), age at menopause (,50, 50 to
,55, 55+ y), benign breast diseases (no, yes), family history of
breast or ovarian cancer (no, yes), and alcohol consumption (0,
,1, 1+ drinks/day). The largest RRs per category increase in the
model (Table 6) were obtained for having used estrogen and
progestin MHT, RR=1.40 (95% CI: 1.32–1.49) per category
increase in duration, and having a history of benign breast
disease/biopsy, RR=1.40 (95% CI: 1.33–1.48).
Endometrial cancer. Of the 146,679 women included in the
final endometrial cancer model, 1,559 were diagnosed with
endometrial carcinoma. The final RR model included BMI
(,25, 25 to ,30, 30 to ,35, 35 to ,40, 40+ kg/m2), MHT use
(never, ,10, 10+ y), parity (0, 1–2, 3+ children), premenopausal
(no, yes), age at menopause (,50, 50 to ,55, 55+ y), smoking
(never, former, current), OC use (,1, 1+ y), and an interaction
term between MHT use and an indicator variable that was one for
BMI,25 kg/m2 and zero otherwise. The largest RRs in the
model were obtained for BMI, fitted with a trend RR=1.72 per
category increase (95% CI: 1.65–1.80); being a never smoker, with
RR=1.47 (95% CI: 1.22–1.78) compared to a current smoker;
and the interaction term between MHT use and the BMI,25 kg/
m2 indicator, RR=1.61 (95% CI: 1.43–1.81) (Table 6).
Ovarian cancer. Among the 199,973 women included in the
ovarian cancer analysis, 844 were diagnosed with ovarian
carcinoma. The final RR model included family history of breast
or ovarian cancer (no, yes), duration of MHT use (never,,10, 10+
y), parity (0, 1–2, 3+ children), and OC use (,1, 1+ y) (Table 6).
The largest RR was seen for OC never use compared to OC ever
use, RR=1.36 (95% CI: 1.17–1.59).
Absolute Risks
The AR estimates used to compute baseline hazard rates for the
models were 0.52 for breast cancer, 0.81 for endometrial cancer,
and 0.43 for ovarian cancer.
Table 7 shows examples of 10- and 20-y absolute risks for
several risk profiles and for initial ages 50 and 65 y. Breast cancer
absolute risk estimates ranged from 1.57% to 21.78% for 10-y
projections and from 3.64% to 35.11% for 20-y projections. Risk
for endometrial cancer ranged from 0.35% to 10.50% for 10-y and
from 1.22% to 17.08% for 20 y. The highest 20-y risk, 17.08%,
was seen for a 65-y-old woman in the 40+ kg/m2 BMI category
who had never smoked. For specific risk factor combinations,
endometrial absolute risk can be higher than breast cancer abso-
lute risk. For example, profile 8 (Table 7) corresponds to a
premenopausal nulliparious 50-y-old woman with a BMI of 35 kg/
m2, who never smoked, has no family history of breast or ovarian
cancer, and never had a breast biopsy. Her 10-y endometrial cancer
absolute risk is 4.9%, while her 10-y absolute risk of breast cancer is
only 1.62%. 10-y absolute risk of ovarian cancer ranged from 0.28%
to 0.96%, and 20-y risk, from 0.74% to 1.77%.
Comprehensive tabulations of 5-, 10-, and 20-y risks for 50- and
60-y-old women for all possible combinations of risk factors for the
three outcomes, and software written in SAS to compute absolute
risk estimates for any age, projection length, and combination of
risk factors, are freely available for download under Breast/
Endometrial/Ovarian Risk Assessment at http://dceg.cancer.
gov/tools/risk-assessment.
Validation of the Models in the Nurses’ Health Study
RR estimates in the NHS cohort for all three cancers (Table 8)
were very similar to those used in the model (Table 6).
Breast cancer. A total of 2,934 incident breast cancers were
diagnosed among women included in the analyses, and the model
predicted 2,930, resulting in an E/O ratio of 1.00 (95% CI: 0.96–
1.04) (Table 9). The model significantly underestimated the number
of breast cancers in premenopausal women. For all other variables,
the E/O ratios were not statistically significantly different from
unity. The overall AUC (discriminatory power) in the NHS cohort
was 0.58 (95% CI: 0.57–0.59). We also compared the performance
of the new breast cancer model to that of NCI’s BCRAT [6] on the
same validation data. BCRAT predicted 2,947 cases, resulting in E/
O=1.00 (95% CI: 0.97–1.04). The number of cases was over-
predicted significantly in cells defined by family history using either
the coding for the newmodel or BCRAT (Table 9). For women with
a family history of breast or ovarian cancer, E/O=1.30 (95% CI:
1.19–1.42), and for women with one and two relatives with breast
cancer, E/O=1.30 (95% CI: 1.18–1.43) and E/O=1.78 (95% CI:
1.25–2.55), respectively. For the new breast cancer model, the
predicted number of cases did not significantly differ from the
observed, with E/O=0.98 (95%CI: 0.89–1.08) for women with one
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first-degree relative with breast cancer and E/O=0.72 (95% CI:
0.50–1.02) for women with two or more relatives with breast cancer.
The overall AUC for BCRAT in the NHS validation data, 0.56
(95% CI: 0.55–0.58), was significantly lower than the AUC for the
new breast cancer model (paired t-test, p,0.001).
Endometrial cancer. The endometrial cancer absolute risk
model predicted 640 cancers, but only 532 incident endometrial
cancers were observed, resulting in E/O=1.20 (95% CI: 1.11–
1.30). The model significantly overestimated the observed NHS
endometrial cancers in most subgroups (Table 10). The number of
endometrial cancers was underestimated for women in the highest
BMI category and for premenopausal women, and significantly
underestimated for women who reported taking MHT for 10 or
more years. The AUC was 0.68 (95% CI: 0.66–0.70).
Ovarian cancer. A total of 377 incident ovarian cancers
were diagnosed among women included in the analyses, and the
model predicted 406 (Table 10), resulting in E/O=1.08 (0.97–
1.19). The number of ovarian cancers was overestimated for all
covariate categories, albeit not statistically significantly, with the
exception of the nulliparous group and women taking MHT for 10
or more years. The AUC was 0.59 (95% CI: 0.56–0.63).
Cross-Classification of Breast and Endometrial Cancer
Risk in the Nurses’ Health Study
Current American Society of Clinical Oncology guidelines
indicate that premenopausal women and postmenopausal women
with low risk of side effects and a 5-y projected BCRAT risk
$1.66% may benefit from tamoxifen and/or raloxifene for breast
cancer prevention [11]. Among the 3,837 premenopausal women
Table 6. Multivariate relative risk estimates for breast, endometrial, and ovarian cancer among non-Hispanic, white women in the
NIH-AARP and PLCO cohorts.
Characteristic Subcategory RR (95% CI)
Breast Cancer Endometrial Cancer Ovarian Cancer
BMI ,25 kg/m2 1.0 (referent) 1.0 (referent) —
Per category increase 1.09 (1.06–1.11) 1.72 (1.65–1.80)
OC use 1+ y — 1.0 (referent) 1.0 (referent)
,1 y 1.44 (1.29–1.62) 1.36 (1.17–1.59)
MHT use Never 1.0 (referent) 1.0 (referent)
Per category increase 1.15 (1.05–1.26) 1.26 (1.15–1.38)
Interaction MHT use with BMI,25 kg/m2 1.61 (1.43–1.81)
Estrogen and progestin MHT use No MTH use 1.0 (referent)
Per category increase 1.40 (1.32–1.49)
Other MHT use No 1.0 (referent)
Yes 1.16 (1.08–1.25)
Age at first live birth ,25 y 1.0 (referent) — —
Per category increase 1.17 (1.12–1.21)
Parity 3+ children 1.0 (referent) 1.0 (referent)
Per category increase 1.21 (1.13–1.29) 1.25 (1.14–1.37)
1+ children 1.0 (referent)
Nulliparous 1.32 (1.23–1.40) — —
Age at menopause ,50 y 1.0 (referent) 1.0 (referent) —
Per category increase 1.18 (1.14–1.22) 1.26 (1.17–1.35)
NA/missing 1.17 (1.14–1.22) 1.29 (1.01–1.63)
Benign breast disease/biopsy No 1.0 (referent)
Yes 1.40 (1.33–1.48)
Family history of breast or ovarian cancer No 1.0 (referent) 1.0 (referent)
Yes 1.39 (1.32–1.47) — 1.27 (1.07–1.50)
Alcohol consumption 0 drinks/day 1.0 (referent) — —
Per category increase 1.12 (1.08–1.17)
Smoking Current smoker — 1.0 (referent) —
Never smoker 1.47 (1.22–1.78)
Former smoker 1.21 (1.00–1.47)
Categories for variables fitted with a trend: Models are adjusted for randomization group in PLCO and calendar time. All variables are coded so that the lowest risk
category is the reference category. BMI: ,25, 25 to ,30, 30 to ,35, and 35+ kg/m2 for breast cancer and ,25, 25 to ,30, 30 to ,35, 35 to ,40, and 40+ kg/m2 for
endometrial cancer; MHT use: never, ,10 y, 10+ y; estrogen and progestin MHT use: never, ,10 y, 10+ y; other/unknown MHT use: no, yes; age at first birth: ,25, 25–
29, and 30+ y; parity: 0, 1–2, and 3+ children for endometrial and ovarian cancer; age at menopause: ,50, 50–54, 55+ y, missing; benign breast diseases/biopsy: no, yes,
missing; alcohol consumption: 0, ,1, 1+ drinks/day.
NA, not applicable.
doi:10.1371/journal.pmed.1001492.t006
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aged 50–55 y at baseline in the NHS cohort who reported having
a uterus during follow-up, 784 had a 5-y absolute breast cancer
risk $1.66%. Of those, three women had a $2% 5-y absolute
endometrial cancer risk. Tamoxifen reduces breast cancer risk by
approximately 50% and increases endometrial cancer risk
approximately 4-fold in older women [9]. Gail et al. [19] and
Freedman et al. [20] weighed the risks and benefits of tamoxifen
assuming average age-specific risks of health outcomes, apart from
breast cancer. Using models both for breast cancer and for
endometrial cancer yields a more accurate weighing of risks and
benefits. For example, based on an average 5-y risk of endometrial
cancer of 0.41% [19], tamoxifen would increase absolute
endometrial cancer risk by 1.23% while reducing a 2.5% breast
cancer risk by 1.25%. These risks and benefits are nearly equal. If,
instead, the woman had an endometrial cancer risk of 2%,
tamoxifen would increase endometrial cancer risk by 6%, which
greatly exceeds the reduction in breast cancer risk. In carefully
balancing risk and benefits, however, the comparative lethality of
the two outcomes might also be an additional important factor in a
decision concerning whether to take tamoxifen.
Discussion
We developed models that predict individualized probabilities
of developing breast, endometrial, and ovarian cancers among US
white women aged 50+ y. We chose these three cancers because
they share several risk factors, presumably reflecting a common
hormonal etiology, and because management decisions may
depend jointly on these risks.
To our knowledge, there is no other absolute risk model for
endometrial cancer, despite the fact that it is the fourth most
common cancer in women [8] and its absolute risks are quite high,
Table 8. Multivariate relative risk estimates for breast, endometrial, and ovarian cancer among non-Hispanic, white women in the
NHS validation cohort.
Characteristic Subcategory RR (95% CI)
Breast Cancer Endometrial Cancer Ovarian Cancer
BMI ,25 kg/m2 1.0 (referent) 1.0 (referent) —
Per category increase 1.11 (1.07–1.16) 1.78 (1.64–1.93) —
OC use 1+ y — 1.0 (referent) 1.0 (referent)
,1 y — 1.30 (1.07–1.57) 1.36 (1.08–1.73)
Estrogen and progestin MHT use No MTH use 1.0 (referent) — —
Per category increase 1.53 (1.37–1.70) — —
Other MHT use No 1.0 (referent) — —
Yes 1.07 (0.98–1.17) — —
MHT use Never — 1.0 (referent) 1.0 (referent)
Per category increase — 2.43 (1.97–2.99) 1.24 (1.05–1.46)
Interaction MHT use with BMI,25 kg/m2 1.41 (1.10–1.80)
Age at first live birth ,25 y 1.0 (referent) — —
Per category increase 1.14 (1.08–1.20) — —
Parity 3+ children — 1.0 (referent) 1.0 (referent)
Per category increase — 1.26 (1.11–1.44) 1.26 (1.08–1.47)
1+ children 1.0 (referent) — —
Nulliparous 1.31 (1.13–1.52) — —
Age at menopause ,50 1.0 (referent) 1.0 (referent) —
Per category increase 1.20 (1.12–1.29) 1.30 (1.12–1.51) —
Premenopausal 1.54 (1.32–1.80) 2.16 (1.57–2.97) —
Benign breast disease/biopsy No 1.0 (referent) — —
Yes 1.34 (1.24–1.44) — —
Family history of breast or ovarian cancer No 1.0 (referent) — 1.0 (referent)
Yes 1.34 (1.22–1.47) — 1.29 (0.98–1.71)
Alcohol consumption 0 drinks/day 1.0 (referent) — —
Per category increase 1.06 (1.00–1.12) — —
Smoking Current smoker — 1.0 (referent) —
Never smoker — 1.82 (1.36–2.44) —
Former smoker — 1.30 (0.96–1.76) —
Categories for variables fitted with a trend: All variables are coded so that the lowest risk category is the reference category. BMI: ,25, 25 to ,30, 30 to ,35, and 35+
kg/m2 for breast cancer and,25, 25 to,30, 30 to,35, 35 to,40, and 40+ kg/m2 for endometrial cancer; estrogen and progestin MHT use: never, ,10 y, 10+ y; other/
unknown MHT use: no, yes; MHT use: never, ,10 y, 10+ y; age at first birth: ,25, 25–29, and 30+ y; parity: 0, 1–2, and 3+ children for endometrial and ovarian cancer;
age at menopause: ,50, 50–54, 55+ y, missing; benign breast disease/biopsy: no, yes, missing; alcohol consumption: 0, ,1, 1+ drinks/day.
doi:10.1371/journal.pmed.1001492.t008
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Table 9. Breast cancer risk predictions during the follow-up of non-Hispanic, white women in the NHS for new breast cancer
model and BCRAT.
Characteristic Observed Breast Cancer Model BCRAT
Expected E/O (95% CI) Expected E/O (95% CI)
All 2,934 2,930 1.00 (0.96–1.04) 2,947 1.00 (0.97–1.04)
BMI
,25 kg/m2 1,447 1,492 1.03 (0.98–1.09) 1,545 1.07 (1.01–1.12)
25 to ,30 kg/m2 971 935 0.96 (0.90–1.03) 930 0.96 (0.90–1.02)
30 to ,35 kg/m2 368 349 0.95 (0.86–1.05) 329 0.89 (0.81–0.99)
35 to ,40 kg/m2 148 154 1.04 (0.89–1.22) 139 0.94 (0.80–1.11)
Duration of estrogen and progestin MHT use
0 2,367 2,402 1.01 (0.97–1.06) 2,517 1.06 (1.02–1.11)
1–9 y 567 527 0.93 (0.86–1.01) 426 0.75 (0.69–0.82)
10+ y 0 2 NA 1 NA
Other MHT use
No 1,746 1,640 0.94 (0.90–0.98) 1,667 0.95 (0.91–1.00)
Yes 1,188 1,290 1.09 (1.03–1.15) 1,277 1.07 (1.02–1.14)
Parity
0 197 201 1.02 (0.89–1.17) 136 0.69 (0.60–0.79)
1+ 2,737 2,729 1.00 (0.96–1.04) 2,807 1.03 (0.99–1.06)
Age at menarche
,12 y 654 623 0.95 (0.88–1.03) 686 1.05 (0.97–1.13)
12–13 y 1,636 1,656 1.01 (0.96–1.06) 1,680 1.03 (0.98–1.08)
$14 y 613 624 1.02 (0.94–1.10) 581 0.95 (0.88–1.03)
Age at first birth
,25 y or nulliparous 1,601 1,586 0.99 (0.94–1.04) 1,586 0.99 (0.94–1.04)
25 to ,30 y 1,024 1,021 1.00 (0.94–1.06) 1,063 1.04 (0.98–1.10)
30+ y 309 323 1.05 (0.94–1.17) 347 1.12 (1.00–1.26)
Age at menopause
,50 y 866 911 1.05 (0.98–1.12)
50–54 y 1,605 1,634 1.02 (0.97–1.07) 1,574 0.98 (0.93–1.03)
55+ y 196 189 0.96 (0.84–1.11) 157 0.80 (0.70–0.92)
Premenopausal 267 196 0.73 (0.65–0.83) 217 0.81 (0.72–0.92)
Benign breast disease
No 1,548 1,517 0.98 (0.93–1.03) 1,863 1.00 (0.95–1.04)
Yes 1,386 1,413 1.02 (0.97–1.07) 1,083 1.02 (0.96–1.09)
Family history of breast or ovarian cancer
No 2,410 2,387 0.99 (0.95–1.03) 2,262 0.94 (0.90–0.98)
Yes 524 543 1.04 (0.95–1.13) 682 1.30 (1.19–1.42)
Number of first-degree relatives with breast cancer
0 2,464 2,475 1.00 (0.97–1.05) 2,328 0.94 (0.91–0.98)
1 435 428 0.98 (0.89–1.08) 565 1.30 (1.18–1.43)
2 30 21 0.72 (0.50–1.02) 53 1.78 (1.25–2.55)
Alcohol consumption
0 drinks/day 1,139 1,091 0.96 (0.90–1.02) 1,185 1.04 (0.98–1.10)
,1 drinks/day 1,389 1,418 1.02 (0.97–1.08) 1,388 1.00 (0.95–1.05)
1+ drinks/day 406 421 1.04 (0.94–1.14) 370 0.91 (0.83–1.00)
NA, not applicable.
doi:10.1371/journal.pmed.1001492.t009
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particularly in obese women (Table 7). Knowledge of endometrial
cancer risk might inform decision-making about diagnostic
workup, clinical management, surgical interventions, and the use
of agents, such as tamoxifen or unopposed estrogen that increase
endometrial cancer risk. Such a model might also aid in designing
intervention trials to prevent endometrial cancer and in identifying
women with elevated risk who might benefit from such interven-
tions. The endometrial cancer model may also be useful in
assessing the burden of that cancer in the general population,
which may increase, as more than a third of all US women now
have a BMI of 30 kg/m2 or higher [21]. In combination with data
on trends in the prevalence of obesity, one could use the model to
investigate the extent to which the increasing prevalence of obesity
accounts for the significant 2% per year increase in endometrial
cancer incidence seen among white women 2006–2010 [22].
Unlike most other models for breast cancer, our model
includes factors that are potentially modifiable for the individual
or in populations over time, such as alcohol consumption, BMI,
and use of MHT. This model had slightly better discriminatory
accuracy (AUC=0.58) in the validation data than the widely
used BCRAT (‘‘Gail model’’) (AUC=0.56), which predicts breast
cancer risk based on reproductive factors, number of breast
biopsies, and atypical hyperplasia. However, despite this increase
in AUC, the discriminatory accuracy of the breast cancer
absolute risk model is still modest, and limits its clinical
applicability, particularly for screening. Several breast cancer
risk prediction models include non-modifiable risk factors such as
family history (e.g., [1]), mammographic density [23–25], and
reproductive and medical factors such as age at menarche and
number of breast biopsies [6]. A few models for US women
include potentially modifiable risk factors, such as BMI and
alcohol use [26]. Our model also incorporates use, and duration
of use, of combined estrogen and progestin MHT and other types
of MHT. Use of estrogen and progestin MHT had the second
largest RR in our model, and had the same RR (RR=1.40) for a
one category increase in duration as benign breast disease.
Petracci et al. [27] illustrate public health and counseling
applications of a breast cancer model with modifiable risk factors
Table 10. Endometrial and ovarian cancer risk prediction during the follow-up of non-Hispanic, white women in the NHS.
Characteristic Endometrial Cancer Ovarian Cancer
Observed Expected E/O (95% CI) Observed Expected E/O (95% CI)
All 532 637 1.20 (1.11–1.29) 377 406 1.08 (0.97–1.19)
BMI
,25 kg/m2 190 235 1.24 (1.09–1.40) — — —
25 to ,30 kg/m2 160 185 1.16 (1.00–1.34) — — —
30 to ,35 kg/m2 96 117 1.22 (1.02–1.46) — — —
35 to ,40 kg/m2 42 57 1.37 (1.06–1.77) — — —
40+ kg/m2 44 42 0.95 (0.70–1.29) — — —
Duration of MHT use
0 y 304 388 1.28 (1.15–1.41) 202 226 1.12 (0.97–1.28)
1–9 y 186 228 1.23 (1.08–1.40) 143 154 1.08 (0.92–1.27)
10+ y 42 21 0.49 (0.32–0.76) 32 26 0.80 (0.57–1.13)
Parity
0 43 52 1.20 (0.91–1.58) 36 33 0.91 (0.66–1.26)
1–2 190 211 1.11 (0.97–1.27) 120 137 1.14 (0.95–1.36)
3+ 299 374 1.25 (1.13–1.38) 221 236 1.07 (0.94–1.22)
Age at menopause
,50 y 123 172 1.39 (1.20–1.62) — — —
50–54 y 291 338 1.16 (1.04–1.29) — — —
55+ y 41 63 1.53 (1.20–1.96) — — —
Premenopausal 77 65 0.84 (0.66–1.07)
Family history of breast or ovarian
cancer
No — — 318 344 1.08 (0.97–1.21)
Yes — — 59 62 1.04 (0.81–1.35)
OC use
Never or ,1 y 367 459 1.25 (1.14–1.37) 270 291 1.08 (0.96–1.21)
1+ y 165 178 1.08 (0.93–1.25) 107 115 1.07 (0.89–1.30)
Smoking
Never 287 318 1.11 (0.99–1.24) — — —
Former 191 243 1.27 (1.12–1.44) — — —
Current 54 76 1.40 (1.12–1.75) — — —
doi:10.1371/journal.pmed.1001492.t010
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in Italian women, and similar calculations could be performed for
the US with the model we developed. These calculations could
also aid in understanding the impact of increases in obesity on US
breast cancer incidence.
For ovarian cancer, a model based on the NHS includes age at
menopause, age at menarche, OC use, and tubal ligation [7].
To build the models, we combined data from two large
prospective studies from well-characterized populations. We used
another large cohort, the NHS cohort, to independently validate
our models. The RR estimates agreed well with those in the NHS
cohort for all three models. The discriminatory power, as assessed
by the AUC, was 0.58 and 0.59 for the breast and ovarian cancer
models, respectively. While these values indicate modest discrim-
inatory ability, they are similar to those reported for other cancer
risk models for these cancers [2,7]. The AUC value for
endometrial cancer was 0.67, which is larger than that seen for
most models of cancer incidence.
The breast and ovarian model were well calibrated in the NHS
cohort; however, because women in the NHS cohort were
censored at the age of diagnosis of an in situ breast cancer, the
breast model may have underestimated slightly. The endometrial
model significantly over-predicted the number of endometrial
cancers. This reflects the fact that the NHS cohort has
considerably lower endometrial cancer rates (Table 3) than those
seen in SEER (Table 4). Further studies of the calibration of this
model in additional cohorts would be desirable to assess its
applicability to the general US population.
Well-calibrated risk models, even those with modest discrimi-
natory accuracy, have several public health applications. These
include designing cancer prevention trials, assessing the absolute
burden of disease in the population and in subgroups, and gauging
the potential absolute reductions in risk from preventive strategies.
Using risk models to select individuals for screening or other
interventions usually requires high discriminatory accuracy [28].
Well-calibrated risk models with modest discriminatory accuracy
can also aid in individual decision-making. Such models can
provide realistic information on level of risk that is useful in
making decisions, such as whether or not to have a mammogram
[29]. Such models are also useful in decisions on whether or not to
take an intervention that has both beneficial and harmful health
effects [19,28].
There are several potential limitations to our models. The exact
number of breast biopsies, an important predictor in BCRAT, was
not available in our cohorts, and the models were restricted to
women aged 50+ y. Our RR models were built using white, non-
Hispanic women and may not generalize to other races or
ethnicities. We adjusted the age-specific endometrial and ovarian
cancer incidence rates for the prevalence of hysterectomy and
oophorectomy among US women estimated from population-
based surveys, but some residual error may exist. Another
limitation is that MHT use was probably more prevalent during
the period of study of PLCO and NIH-AARP, from 1993 to 2005,
than it is currently. While such changes in the prevalence of risk
factors would not affect model calibration, they could reduce the
variation of risk in the population and hence reduce the
discriminatory accuracy of the models. Among the strengths of
our models are large study sample size, nearly complete end point
ascertainment, and information on most of the important risk
factors.
Our models are not intended to predict the probability of the
three cancers among women known to be at much higher than
average risk, e.g., women with a mutation in BRCA1 or BRCA2 or
with hereditary non-polyposis colorectal cancer (HNPCC). Each
model is applicable to women without a prior diagnosis of that
particular cancer, and thus in principle the breast cancer model
can be applied to predict breast cancer risk for women with a prior
diagnosis of any other cancer, including endometrial cancer.
However, in applying the risk estimates, one needs to consider that
a woman’s risk may be altered by treatment for a previous cancer.
In conclusion, we developed and assessed models that project
the probabilities of developing breast, endometrial, or ovarian
cancer among white, non-Hispanic women aged 50+ y. These
models might improve the ability to identify potential participants
for research studies and assist in clinical decision-making related to
the risks of these cancers.
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Editors’ Summary
Background. In 2008, just three types of cancer accounted
for 10% of global cancer-related deaths. That year, about
460,000 women died from breast cancer (the most
frequently diagnosed cancer among women and the fifth
most common cause of cancer-related death). Another
140,000 women died from ovarian cancer, and 74,000 died
from endometrial (womb) cancer (the 14th and 20th most
common causes of cancer-related death, respectively).
Although these three cancers originate in different tissues,
they nevertheless share many risk factors. For example,
current age, age at menarche (first period), and parity (the
number of children a woman has had) are all strongly
associated with breast, ovarian, and endometrial cancer risk.
Because these cancers share many hormonal and epidemi-
ological risk factors, a woman with a high breast cancer risk is
also likely to have an above-average risk of developing
ovarian or endometrial cancer.
Why Was This Study Done? Several statistical models (for
example, the Breast Cancer Risk Assessment Tool) have been
developed that estimate a woman’s absolute risk (probabil-
ity) of developing breast cancer over the next few years or
over her lifetime. Absolute risk prediction models are useful
in the design of cancer prevention trials and can also help
women make informed decisions about cancer prevention
and treatment options. For example, a woman at high risk of
breast cancer might decide to take tamoxifen for breast
cancer prevention, but ideally she needs to know her
absolute endometrial cancer risk before doing so because
tamoxifen increases the risk of this cancer. Similarly,
knowledge of her ovarian cancer risk might influence a
woman’s decision regarding prophylactic removal of her
ovaries to reduce her breast cancer risk. There are few
absolute risk prediction models for ovarian cancer, and none
for endometrial cancer, so here the researchers develop
models to predict the risk of these cancers and of breast
cancer.
What Did the Researchers Do and Find? Absolute risk
prediction models are constructed by combining estimates
for risk factors from cohorts with population-based incidence
rates from cancer registries. Models are validated in an
independent cohort by testing their ability to identify people
with the disease in an independent cohort and their ability
to predict the observed numbers of incident cases. The
researchers used data on white, non-Hispanic women aged
50 years or older that were collected during two large
prospective US cohort studies of cancer screening and of
diet and health, and US cancer incidence and mortality rates
provided by the Surveillance, Epidemiology, and End Results
Program to build their models. The models all included parity
as a risk factor, as well as other factors. The model for
endometrial cancer, for example, also included menopausal
status, age at menopause, body mass index (an indicator of
the amount of body fat), oral contraceptive use, menopausal
hormone therapy use, and an interaction term between
menopausal hormone therapy use and body mass index.
Individual women’s risk for endometrial cancer calculated
using this model ranged from 1.22% to 17.8% over the next
20 years depending on their exposure to various risk factors.
Validation of the models using data from the US Nurses’
Health Study indicated that the endometrial cancer model
overestimated the risk of endometrial cancer but that the
breast and ovarian cancer models were well calibrated—the
predicted and observed risks for these cancers in the
validation cohort agreed closely. Finally, the discriminatory
power of the models (a measure of how well a model
separates people who have a disease from people who do
not have the disease) was modest for the breast and ovarian
cancer models but somewhat better for the endometrial
cancer model.
What Do These Findings Mean? These findings show
that breast, ovarian, and endometrial cancer can all be
predicted using information on known risk factors for these
cancers that is easily obtainable. Because these models were
constructed and validated using data from white, non-
Hispanic women aged 50 years or older, they may not
accurately predict absolute risk for these cancers for women
of other races or ethnicities. Moreover, the modest discrim-
inatory power of the breast and ovarian cancer models
means they cannot be used to decide which women should
be routinely screened for these cancers. Importantly,
however, these well-calibrated models should provide
realistic information about an individual’s risk of developing
breast, ovarian, or endometrial cancer that can be used in
clinical decision-making and that may assist in the identifi-
cation of potential participants for research studies.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001492.
N This study is further discussed in a PLOS Medicine
Perspective by Lars Holmberg and Andrew Vickers
N The US National Cancer Institute provides comprehensive
information about cancer (in English and Spanish),
including detailed information about breast cancer,
ovarian cancer, and endometrial cancer;
N Information on the Breast Cancer Risk Assessment Tool,
the Surveillance, Epidemiology, and End Results Program,
and on the prospective cohort study of screening and the
diet and health study that provided the data used to build
the models is also available on the NCI site
N Cancer Research UK, a not-for-profit organization, provides
information about cancer, including detailed information
on breast cancer, ovarian cancer, and endometrial cancer
N The UK National Health Service Choices website has
information and personal stories about breast cancer,
ovarian cancer, and endometrial cancer; the not-for-profit
organization Healthtalkonline also provides personal sto-
ries about dealing with breast cancer and ovarian cancer
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